The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001253392p
Ethics application status
Help: Ethics application status
Not yet submitted
Date submitted
Help: Date submitted
24/09/2026
Date registered
Help: Date registered
14/10/2026
Date last updated
Help: Date last updated
14/10/2026
Date data sharing statement initially provided
Help: Data sharing statement date
14/10/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
An Australasian Leukaemia and Lymphoma Group (ALLG) phase II, multicenter, open-label trial evaluating the efficacy and safety of ELVN-001 in patients With Chronic Myeloid Leukemia (CML).
Scientific title
An ALLG phase II, multicenter, open-label trial evaluating the efficacy and safety of ELVN-001 in patients With Chronic Myeloid Leukemia (CML).
Additional trial identifiers [1] 318520 0
ALLG CML15
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Chronic Myeloid Leukaemia 343707 0
Condition category
Condition code
Cancer 339822 339822 0 0
Leukaemia - Chronic leukaemia

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Patients will receive an oral tablet (80mg) of ELVN-001 given once a day with a large glass of water at the same time each day.

Treatment cycles are for 28 days and administered continuously. The total treatment duration is about 4-5 years. Participants will be eligible for treatment-free remission (TFR) after taking ELVN-001 for at least 4 years, with no signs of the cancer returning for at least 2 years.

Patients will be checked at the hospital after taking the drug for 1 week, then at each month until 3 months, then every 3 months until 5 years.

All treatment will be administered by the study team (i.e., registered nurse, the lead physician, physicians listed on the trial to assist the lead physician). Drug accountability will be performed by the administering institutions to assess compliance through pharmacy dispensing logs, dose administration records, and verifying patient diaries.

Intervention code [1] 335420 0
Treatment: Drugs
Description of the comparator or control
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 346994 0
major molecular response (MMR)
Timepoint [1] 346994 0
12 months after starting study treatment
Secondary outcome [1] 468513 0
Early molecular response (EMR)
Timepoint [1] 468513 0
3 months after starting treatment.
Secondary outcome [2] 468514 0
Molecular Response (MR)4.0
Timepoint [2] 468514 0
12 and 24 months after starting treatment
Secondary outcome [3] 468515 0
Molecular Response (MR)4.5
Timepoint [3] 468515 0
12, 24,36, 48, and 60 months after starting treatment
Secondary outcome [4] 468516 0
MMR
Timepoint [4] 468516 0
6, 12, 18, 24, 36, 48, and 60 months after starting treatment
Secondary outcome [5] 468517 0
Cumulative incidence of MMR, with competing risks of transformation to Accelerated Phase (AP)/Blast Crisis (BC).
Timepoint [5] 468517 0
3, 6, 12, 18, 24, 36, 48, and 60 months after starting treatment
Secondary outcome [6] 468518 0
Durability of MMR Response
Timepoint [6] 468518 0
From date of first documented MMR until loss of response, relapse, progression, death until 5 years after starting treatment.
Secondary outcome [7] 468521 0
Overall Survival
Timepoint [7] 468521 0
From the date of registration to the date of death from any cause.
Secondary outcome [8] 468522 0
Transformation-free survival
Timepoint [8] 468522 0
From the date of registration to the date of death from any cause, event, or discontinuation of protocol therapy for other reasons.
Secondary outcome [9] 468523 0
Event-free survival (EFS)
Timepoint [9] 468523 0
From the date of registration to the date of death from any cause, event, or discontinuation of protocol therapy for other reasons until end of 5 years from start of treatment.
Secondary outcome [10] 468524 0
Safety
Timepoint [10] 468524 0
At all scheduled timepoints of trial treatment: baseline, days 8, 29 & 57, then every 3 months until end of 5 years from start of treatment.
Secondary outcome [11] 468525 0
Tolerability
Timepoint [11] 468525 0
At all scheduled timepoints of trial treatment: baseline, days 8, 29 & 57, then every 3 months until end of 5 years from start of treatment.
Secondary outcome [12] 468982 0
MR4.0
Timepoint [12] 468982 0
3, 6, 12, 18, 24, 36, 48, and 60 months after starting treatment
Secondary outcome [13] 468983 0
MR4.5
Timepoint [13] 468983 0
3, 6, 12, 18, 24, 36, 48, and 60 months after starting treatment
Secondary outcome [14] 468984 0
Cumulative incidence of MR4.0, with competing risks of transformation to Accelerated Phase (AP)/Blast Crisis (BC).
Timepoint [14] 468984 0
3, 6, 12, 18, 24, 36, 48, and 60 months after starting treatment
Secondary outcome [15] 468985 0
Cumulative incidence of MR4.5, with competing risks of transformation to Accelerated Phase (AP)/Blast Crisis (BC).
Timepoint [15] 468985 0
3, 6, 12, 18, 24, 36, 48, and 60 months after starting treatment
Secondary outcome [16] 468986 0
Durability of Response of MR4.0
Timepoint [16] 468986 0
From date of first documented MR4.0 until loss of response, relapse, progression, death until 5 years after starting treatment.
Secondary outcome [17] 468987 0
Durability of Response of MR4.5
Timepoint [17] 468987 0
From date of first documented MR4.5 until loss of response, relapse, progression, death until 5 years after starting treatment.

Eligibility
Key inclusion criteria
1. Patients or their legally authorised representative must voluntarily sign and date an informed consent, approved by a Human Research Ethics Committee (HREC), prior to the initiation of any screening or trial-specific procedures.
2. Are willing and able to comply with procedures required in this protocol.
3. Age greater than 18 years.
4. Newly diagnosed Philadelphia chromosome-positive Chronic Phase Chronic Myeloid Leukaemia (Ph+ CP-CML) patients aged 18 years or older.
a. Must have BCR::ABL1 transcript variants e13a2 (b2a2), BCR exon 13 fused to ABL1 exon 2; and/or e14a2 (b3a2), BCR exon 14 fused to ABL1 exon 2; or e1a2, BCR exon 1 fused to ABL1 exon 2, at screening.
b. Must have a bone marrow aspirate confirming chronic phase as per the World Health Organization (WHO) 2022 criteria.
c. Blast cells in blood and bone marrow less than 20%.
d. No extramedullary blast proliferation.
e. Lymphoblast population not exceeding 0.4%.
5. No prior Tyrosine Kinase Inhibitor (TKI) exposure of greater than 14 days. Hydroxyurea and anagrelide are allowed prior to, and up to 1 week after starting Chronic Myeloid Leukaemia 15 (CML15) trial treatment. Leukapheresis (collection of white blood cells from the blood) is permitted as clinically indicated.
6. Must be less than or equal to 3 months from diagnosis to screening.
7. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2
8. Co-enrolment to the Australasian Leukaemia and Lymphoma Group (ALLG) National Blood Cancer Registry (NBCR).
9. Based on known medical history, expected to have a life expectancy greater than or equal to 12 months.
10. Patients of childbearing potential must have a negative serum pregnancy test 10 to 14 days prior to registration and again within 24 hours prior to registration. The pregnancy test must be sensitive to at least 25 International Units per Litre (IU/L).
11. Patients must not be breastfeeding.
12. Patients of childbearing potential must agree to practice one protocol-specified method of birth control that is effective from trial registration up to 90 days after the last dose of trial drug. Patients of non-childbearing potential do not need to use birth control. Approved methods of birth control are:
a) Combined (estrogen- and progestogen-containing) hormonal contraception (oral, intravaginal, transdermal) associated with inhibition of ovulation, from registration up to 90 days after the last dose of treatment.
b) Progestogen-only hormonal contraception (oral, injectable, implantable) associated with inhibition of ovulation, from registration up to 90 days after the last dose of trial drug.
c) Bilateral tubal occlusion/ligation or bilateral tubal occlusion via hysteroscopy (for example, Essure), provided a hysterosalpingogram confirms success of the procedure.
d) Vasectomised partner(s), provided the vasectomised partner verbally confirms they are the sole sexual partner of the woman of childbearing potential (WOCBP) trial patient and the absence of sperm has been confirmed.
e) Intrauterine Device (IUD).
f) Intrauterine Hormone-Releasing System (IUS).
g) True abstinence: Refraining from heterosexual intercourse when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (for example, calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable.
13. Patients who are sexually active with partner(s) of childbearing potential must agree, from registration up to 90 days after the last dose of trial drug, to practice the protocol-specified contraception, particularly a latex or synthetic condom every time they have sexual intercourse with a partner of reproductive potential, even if they have undergone a successful vasectomy. Azoospermic patients (absence of sperm in the semen) are exempt from contraceptive requirements.

Note:
For the purposes of this trial, a patient of childbearing potential is defined as a sexually mature woman who:
1) Has not undergone hysterectomy or bilateral oophorectomy (surgical removal of both ovaries); or
2) Has not been naturally postmenopausal for at least 12 consecutive months. Amenorrhoea (absence of menstrual periods) following cancer therapy does not rule out childbearing potential.
In other words, the patient has had menses at any time during the preceding 12 consecutive months.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
1. Abnormal clinical laboratory results:
a) Total bilirubin greater than 1.5 times the Upper Limit of Normal (ULN). In patients with Gilbert's syndrome, total bilirubin greater than 3 times the Upper Limit of Normal or direct bilirubin greater than 1.5 times the Upper Limit of Normal.
b) Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) greater than 3 times the Upper Limit of Normal.
c) Alkaline phosphatase greater than 2.5 times the Upper Limit of Normal unless considered to be not of hepatic (liver) origin.
d) Creatinine greater than 1.5 times the Upper Limit of Normal.
e) Amylase or Lipase values greater than 1.5 times the institutional Upper Limit of Normal.
2. Active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of the nail beds) requiring systemic therapy or antibiotics within 14 days prior to registration.
3. Underlying medical conditions that, in the investigator's opinion, will render the administration of trial drug hazardous or obscure the interpretation of safety or efficacy results.
4. Positive serology for Human Immunodeficiency Virus (HIV).
5. Active Hepatitis B Virus (HBV) infection, defined as the presence of detectable HBV Deoxyribonucleic Acid (DNA) or HBV antigens.
Patients who are Hepatitis B Virus Core Antibody (HBVcAb) positive but are HBV DNA and Hepatitis B Virus Surface Antigen (HBVsAg) negative are eligible. These patients will have monthly monitoring of HBV DNA for the duration of the trial and receive appropriate antiviral prophylaxis, such as entecavir, according to advice from the infectious diseases service.
Please note that patients who have received Intravenous Immunoglobulin (IVIG) may have false-positive HBVcAb results. In such patients, if HBV DNA and HBVsAg are negative, prophylaxis may be omitted if considered unnecessary by the infectious diseases service, but monitoring of HBV DNA levels is still required.
6. History of other prior malignancies, except:
a) Malignancy treated with curative intent and with no known active disease present for greater than or equal to 3 years before the first dose of trial drug and considered by the treating physician to be at low risk for recurrence.
b) Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
c) Adequately treated carcinoma in situ without evidence of disease.
d) Localised prostate cancer following radical prostatectomy or with non-rising Prostate-Specific Antigen (PSA) levels less than 0.1 nanograms per millilitre (ng/mL).
7. A history of concomitant primary malignant disease that requires active cytotoxic treatment and/or a life-limiting illness expected to have a life expectancy of less than 5 years.
8. History of significant congenital or acquired bleeding disorder unrelated to cancer.
9. Serious medical or psychiatric illness likely to interfere with safety and efficacy monitoring or otherwise jeopardise the patient's health during this clinical study.
10. Uncontrolled cardiovascular condition, including ongoing cardiac arrhythmias (for example, ventricular arrhythmias, Torsades de Pointes, or third-degree heart block without pacemaker insertion), congestive heart failure, angina, or myocardial infarction within the past 3 months prior to screening.
11. Other concurrent uncontrolled medical conditions that could cause unacceptable safety risks or compromise compliance with the protocol.
12. History of acute pancreatitis within 1 year of Chronic Myeloid Leukaemia 15 (CML15) trial registration, chronic pancreatitis, or any ongoing pancreatic disease.
13. Acute or chronic active liver disease. (Hepatitis B Virus Core Antibody positivity is not an automatic exclusion.)
14. Patients unable to comply with contraception requirements as specified in the CML15 trial.
15. Current participation in another therapeutic clinical trial. Participation in clinical research without active interventions, for example registries, is not an exclusion for the trial.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,TAS,WA,VIC

Funding & Sponsors
Funding source category [1] 323106 0
Other Collaborative groups
Name [1] 323106 0
Australasian Leukaemia and Lymphoma Group
Country [1] 323106 0
Australia
Primary sponsor type
Other Collaborative groups
Name
Australasian Leukaemia and Lymphoma Group
Address
Country
Australia
Secondary sponsor category [1] 326052 0
None
Name [1] 326052 0
Address [1] 326052 0
Country [1] 326052 0

Ethics approval
Ethics application status
Not yet submitted
Ethics committee name [1] 321500 0
Central Adelaide Local Health Network HREC
Ethics committee address [1] 321500 0
Ethics committee country [1] 321500 0
Australia
Date submitted for ethics approval [1] 321500 0
22/03/2027
Approval date [1] 321500 0
Ethics approval number [1] 321500 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 153910 0
Dr David Yeung
Address 153910 0
Royal Adelaide Hospital, Level 3G, Port Road, Adelaide, SA 5000
Country 153910 0
Australia
Phone 153910 0
+61 8 7074 2634
Fax 153910 0
Email 153910 0
Contact person for public queries
Name 153911 0
Delaine Smith
Address 153911 0
ALLG 35 Elizabeth St Richmond Vic 3121
Country 153911 0
Australia
Phone 153911 0
+61 03 83739701
Fax 153911 0
Email 153911 0
Contact person for scientific queries
Name 153912 0
Delaine Smith
Address 153912 0
ALLG 35 Elizabeth St Richmond Vic 3121
Country 153912 0
Australia
Phone 153912 0
+61 03 83739701
Fax 153912 0
Email 153912 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
What individual participant data might be shared?
• All de-identified individual participant data
What types of analyses could be done with individual participant data?
• Any type of analysis (i.e. no restrictions on data re-use)
When can requests for individual participant data be made (start and end dates)?
From:
3 months after publication

To:
No end date
Where can requests to access individual participant data be made, or data be obtained directly?
• Data sharing request system: Health Data Australia catalogue (e.g. https://researchdata.edu.au/health/). Please email enquiries to [email protected]


Are there extra considerations when requesting access to individual participant data?
No


What supporting documents are/will be available?

TypeCitationLinkEmailOther DetailsAttachment
Study protocol  [email protected] Access can be requested via the Health Data Austra... [More Details]


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.